Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.45 |
| ▸ | IKZF3 | Q9UKT9 | 6/20 | 0.42 |
| ▸ | TNF | P01375 | 3/20 | 0.42 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | IL1B | P01584 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.35 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24419405 | 0.84 | CRBN (0.44) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL12041906 | 0.83 | CRBN (0.61) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL31023064 | 0.83 | CRBN (0.50) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL24160836 | 0.83 | CRBN (0.50) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL21997269 | 0.83 | CRBN (0.62) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL23355848 | 0.83 | CRBN (0.50) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL24160837 | 0.81 | CRBN (0.45) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL20994647 | 0.81 | CRBN (0.48) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL24745075 | 0.81 | CRBN (0.48) | CRBNDDB1IKZF3TNFIKZF1 | |
| SCHEMBL25473511 | 0.79 | CRBN (0.70) | CRBNDDB1IKZF3TNFIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220313829-A1 | EGFR PROTEIN DEGRADANT AND ANTI-TUMOR APPLICATION THEREOF | EGFR, ERBB2, ERBB3 | CRBN 3528/4885DDB1 1479/4885IKZF3 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.